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ignored diagnosis and in limited management and treatment. The aim of this study 
was	to	compare	the	plasma	proteome	of	RLS	patients	and	healthy	controls,	 in	the	
search of diagnostic biomarkers related to the disease severity.




symptoms),	 and	17	 age-	 and	 sex-	matched	 control	 subjects.	 Sleep	quality,	 daytime	
sleepiness,	and	the	level	of	depression	were	also	evaluated.
Results:	We	 identified	eight	upregulated	 spots,	 corresponding	 to	 five	unique	pro-
teins,	 in	both	RLS	group	vs.	controls	(alpha-	1B-	glycoprotein,	alpha-	1-	acid	glycopro-
tein	 1,	 haptoglobin,	 complement	C4-	A,	 and	 immunoglobulin	 kappa	 constant);	 five	
increased	spots,	consistent	with	three	unique	proteins,	only	in	HS-	RLS	(kininogen-	1,	
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1  | INTRODUC TION
Restless	 legs	 syndrome	 (RLS),	 also	 called	Willis–Ekbom	disease,	 is	


















kidney	disease(Novak,	Winkelman,	&	Unruh,	 2015),	 and	 iron	 defi-
ciency	(Connor,	2008),	as	well	as	various	consequences	of	the	syn-
drome,	 such	as	 insomnia,	 anxiety,	 and	depression	 (Earley	&	Silber,	
2010).
To	date,	 the	pathophysiology	of	primary	RLS	 is	still	 largely	un-
known,	 although	 dysfunctions	 in	 the	 dopaminergic	 system	 are	
suspected to have a role in its development. In support of this as-
sumption is that the current agents of choice for moderate- to- severe 
RLS	are	non-	ergot-	derived	dopamine	receptor	agonists,	even	if	aug-
mentation is a known complication of dopaminergic medications 
(Nagandla	&	De,	2013).





2003).	Nowadays,	 there	are	no	standardized	diagnostic	 tests	 for	
RLS;	poor	 recognition	or	 strange	description	of	 symptoms	often	
causes	 delay	 in	 the	 diagnosis	 or,	 even	worse,	 in	misdiagnosis	 of	






tification of novel diagnostically relevant biomarkers can derive 
from	proteomic	discovery	 strategies	 (Crutchfild,	 Thomas,	 Sokoll,	
&	Chan,	2016).	To	our	knowledge,	only	one	proteomic	study	was	
previously	conducted	to	search	RLS	biomarkers	in	the	cerebrospi-





requires	 a	 more	 complex	 and	 potentially	 dangerous	 procedure	
than	blood,	that,	moreover,	represents	a	reasonable	source	of	bio-
markers	because	 it	 is	 directly	 exposed	 to	 all	 organs	of	 the	body	
and thus can be an archive of all ongoing processes.
The primary objective of our study was to analyze the plasma 
of	RLS	patients	in	comparison	with	healthy	control	subjects,	in	the	
search	 of	 potential	 diagnostic	 biomarkers	 of	 RLS,	 also	 consider-
ing the possible association with the disease severity. We applied 
proteomics methods based on two- dimensional gel electrophore-
sis	 (2-	DE)	 coupled	 to	 liquid	 chromatography-	mass	 spectrometry	
analysis.
2  | MATERIAL S AND METHODS
2.1 | Patients and controls selection
Primary	RLS	patients	(n	=	34)	and	healthy	subjects	as	control	group	
(n	=	17)	 from	 the	 medical	 staff	 were	 recruited	 at	 the	 Neurology	
Department	 of	 Bakirkoy	 Psychiatry	 and	 Neurology	 Research	 and	
Training	Hospital	Sleep	Disorders	Center	(Istanbul,	Turkey).
For	 all	 study	 participants,	 exclusion	 criteria	 were	 as	 follows:	
systemic	 or	 neurologic	 diseases,	 other	 diagnosed	 sleep	 disorders,	
anemia,	iron	deficiency,	uremia,	thyroid	disorders,	use	of	antidepres-
sants	and	antipsychotics,	excessive	alcohol	intake.
All	 patients	 were	 diagnosed	 as	 primary	 RLS	 according	 to	 the	





(IRLS	 scores	 21–30),	 and	 very	 severe	 (IRLS	 scores	 31–40)	 (Allen	
et	al.,	2014).
Based	on	 the	 results,	RLS	patients	were	divided	 into	 two	sub-
groups:	low-	medium	severity	(MMS)	group,	(n	=	17)	including	all	pa-




The study received the approval of the local Ethical Committee 
and was carried out in conformity with the Helsinki Declaration. 





Index	 (PSQI)	 (Buysse,	 Reynolds,	 Monk,	 Berman,	 &	 Kupfer,	 1989);	 
(c)	the	daytime	sleepiness	and	tendency	to	sleep	during	the	day	by	
the	Epworth	Sleepiness	Scale	(ESS;	Izci	et	al.,	2008).
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2.3 | Plasma samples collection and treatment





ferent pools per group.
Moreover,	in	biomarkers	discovery	studies,	depletion	strategies	
are necessary to decrease the high dynamic concentration range 





proteins,	 using	 the	 ProteoPrep®	 Immunoaffinity	 Albumin	 and	
IgG	 Depletion	 Kit	 (Sigma),	 that	 specifically	 removes	 these	 pro-
teins	by	an	immunodepletion	method	(Bellei	et	al.,	2011).	Finally,	
total protein content was measured spectrophotometrically at λ 
595	nm.
2.4 | Two- dimensional gel electrophoresis (2- DE)
Protein separation was performed on depleted plasma samples 
by	 2-	DE,	 as	 previously	 described	 (Bellei	 et	al.,	 2017).	 Briefly,	
80 μg of protein was diluted with rehydration buffer and then 
loaded onto 7- cm- long immobilized pH gradient strips (Ready 
IPG	Strip™,	Bio-	Rad),	pH	range	3–10.	Afterward,	the	strips	were	
first subjected to isoelectric focusing and then to the second- 
dimension	separation	on	10%	polyacrylamide	gels,	 stained	with	
Coomassie	 Blue.	 The	 gel	 images	were	 acquired	 by	 a	 calibrated	
densitometer	 (GS-	800,	 Bio-	Rad)	 and	 analyzed	 by	 the	 PDQuest	
2-	D	 image	 analysis	 software	 (Bio-	Rad),	 as	 previously	 reported	
(Bellei	et	al.,	2017).
2.5 | Mass spectrometry analysis and protein 
identification
The	differentially	expressed	protein	spots	were	“in-	gel”	digested	
with	 trypsin,	 to	obtain	peptides	mixture	 to	be	analyzed	 through	
MS,	as	previously	described	(Bellei	et	al.,	2011).	The	concentrated	
peptides	were	 analyzed	 by	 a	 LC-	Chip-	MS	 System,	 composed	 of	
the	 Electrospray	 Ionization	 Quadrupole-	Time	 of	 Flight	 Mass	
Spectrometer	 (ESI-	Q-	ToF-	MS)	 (Accurate-	Mass	 G6520,	 Agilent	
Technologies)	 connected	 to	 a	 Nano	HPLC-	Chip	microfluidic	 de-
vice	(1200	Nano	HPLC-	Chip,	Agilent	Technologies).	The	MASCOT	
search	engine	(http://mascot.cigs.unimo.it/mascot),	together	with	
the	UniProt	 knowledgebase	 database,	was	 used	 for	 peptide	 se-
quence	searching.	The	highest	score	hits	among	MASCOT	search	
results	 were	 selected,	 and	 proteins	 were	 considered	 identified	
with	at	 least	 two	unique	peptides.	Moreover,	protein	 identifica-
tion	was	 repeated	at	 least	once,	using	spots	extracted	 from	dif-
ferent gel.
2.6 | Statistical analysis
The	 Student’s	 t test was used to compare demographic and clini-
cal	data	of	RLS	patients	and	control	subjects,	considering	a	p- value 
<0.05	as	statistically	significant.	All	reported	data	are	expressed	as	





HS- RLS  
(n = 17) p- Value
Age 44.5	±	7.0 45.1	±	11.0 44.6	±	6.9 0.941a
0.896b
Gender
Male 5	(29.4%) 7	(41.2%) 5	(29.4%) 1.000a
Female 12	(70.6%) 10	(58.8%) 12	(70.6%) 0.488b
RLS	onset
<3months — 2	(11.8%) 1	(5.9%) 0.463b
3months–1year — 2	(11.8%) 1	(5.9%)
1–5years — 5	(29.4%) 5	(29.4%)
>5years — 8	(47.0%) 10	(58.8%)
Iron parameters
Hemoglobin	(g/dl) — 13.9	±	1.3 13.7 ± 1.2 0.578b
Hematocrit	(%) — 41.4	±	6.0 41.6	±	3.6 0.923b
Mean	cell	volume	(fl) — 86.6	±	4.1 85.0	±	3.5 0.241b
Serum	iron	(μg/dl) — 113.3	±	69 78.7 ± 30.8 0.069b
Ferritin (μg/L) — 83.0	±	51.7 68.9	±	38.7 0.395b
Notes.	Age	data	and	iron	parameters	are	expressed	as	mean	±	standard	deviation.
p-	Value	based	on	the	Student’s	t test: aHS-	RLS	vs.	controls;	bHS-	RLS	vs.	MMS-	RLS	group.
TABLE  1 Demographic and clinical 
data	of	RLS	patients	and	controls
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3  | RESULTS
3.1 | Patients and controls data











The results obtained from the patients rating scales are illus-
trated	 in	 Figure	1.	 According	 to	 the	 Beck	 Depression	 Inventory	
Scale	 (Figure	1a),	 15	MMS-	RLS	patients	 (88%)	were	without	 de-
pression	symptoms	and	only	two	(12%)	presented	serious	depres-
sion,	while	in	HS	group	the	36%	of	patients	showed	mild-	serious	




points,	 reporting	excessive	daytime	 sleepiness,	 compared	 to	 the	
24%	(four	patients)	of	HS	group.
3.2 | Bidimensional gel electrophoresis and mass 
spectrometry analysis
The	2D-	gel	maps	were	 analyzed	by	 the	PDQuest	 image	analysis	
software,	after	a	normalization	step	to	correct	the	variability	due	
to	 the	 staining	 process.	 A	 total	 of	 15	 protein	 spots	were	 found	
differentially	expressed	between	RLS	and	controls	 (Figure	2).	All	
the	selected	spots	were	identified	by	ESI-	Q-	ToF-	MS	analysis;	the	
characterized	 proteins	 are	 listed	 in	 Table	2,	 wherein	 the	 alpha-













































p = 0.172                                                p = 0.019                                            p = 0.096
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Five	spots,	corresponding	to	three	unique	proteins,	were	found	
upregulated	 only	 in	 HS-	RLS	 group:	 kininogen-	1	 (KNG1),	 immu-
noglobulin	 heavy	 constant	 alpha	 1	 (IGHA1),	 and	 immunoglobulin	
lambda	 constant	 2	 (IGLC2);	 this	 latter	 with	 the	 higher	 expression	







cult. There is a great need for intensive basic and clinical research to 
discover	new	and	reliable	biomarkers,	useful	firstly	for	a	proper	diag-










to be involved in the regulation of vascular smooth muscle cells and 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Another	 protein,	 CO3,	 was	 found	 downregulated	 in	 both	 RLS	
groups vs. controls. Complement acts as a rapid and efficient im-
mune	 surveillance	 system,	 with	 different	 effects	 on	 both	 healthy	
and	altered	host	cells,	other	than	to	be	involved	in	homeostasis	con-
trol	and	 in	 inflammatory	processes	 (Ricklin,	Hajishengallis,	Yang,	&	
Lambris,	2010).	In	consequence,	defective	control	of	the	complement	
cascade,	or	of	its	regulation,	is	associated	with	several	disorders.	A	





of	 the	 same	 protein),	 and	 spot	 L9	 (derived	 from	 protein	 fragmen-
tation),	were	 identified	 as	HPT	by	MS.	HPT	plasma	 concentration	
increases	several	folds	in	case	of	inflammatory	stimulus;	therefore,	it	











port	 activity,	 as	well	 as	 immunomodulatory	and	anti-	inflammatory	
roles	 (Hochepied,	 Berger,	 Baumann,	 &	 Libert,	 2003).	 The	 overex-
pression	 of	 A1AG1	 and	 HPT	 observed	 in	 plasma	 of	 RLS	 patients	









sulted	 upregulated	 in	 both	 RLS	 group	 vs.	 controls,	 independently	
from	the	disease	severity	score	(Table	2).	A1BG	is	a	secreted	plasma	
protein and a member of the immunoglobulin superfamily with a rea-
sonable	role	 in	 the	 immune	system	and	 in	cell	adhesion	 (Halaby	&	
Mornon,	1998).	In	literature	are	reported	conflicting	data	concerning	
the	 expression	of	A1BG.	For	 example,	 in	 neuromyelitis	 optica	has	
been	found	a	reduced	expression	of	A1BG	in	CSF	of	patients	com-
pared	 to	 controls	 (Bai	 et	al.,	 2009).	Conversely,	 in	 case	of	 autoim-
mune	disorders,	which	frequently	are	associated	with	RLS,	Biswas	
et	al.	 (2013)have	 identified,	 by	 an	 immunoproteomic	 approach,	 a	






a mediator of local inflammatory processes. This further strengthens 














dicate a progressively greater involvement of immunological mech-
anisms	with	 the	worsening	of	 the	disease.	Noteworthy,	as	evident	
in	Table	2,	 IGLC2	 showed	 the	higher	 level	 of	 protein	 spot	 expres-
sion	 change	 vs.	MMS-	RLS	 group	 (+10.64).	A	massive	 upregulation	




This is a major component of plasma kallikrein- kinin system and a 
bradykinin	 precursor,	 a	 nanopeptide	with	 strong	 vasoactive	 and	
proinflammatory	 properties.	 Studies	 on	 KNG1-	deficients	 mice	
demonstrated an important role of this protein in the pathogen-
esis	 of	 autoantibody-	induced	 arthritis,	 proposing	 the	 block	 of	
KNG1	 cleavage	 as	 a	 novel	 therapeutic	 strategy	 for	 rheumatoid	
arthritis	 treatment	 (Xie,	 Dai,	 &	 Wu,	 2016).	 A	 study	 conducted	
in	mice	 recognized	 KNG1	 as	 a	 key	mediator	 of	 ischemic	 neuro-
degeneration and neuronal damage by increasing microvascular 
thrombosis,	blood–brain	barrier	leakage	and	inflammation;	KNG1	
inhibition allowed to protect from thromboembolic disorders and 
stroke	(Langhauser	et	al.,	2012).	In	humans,	extreme	levels	of	high-	
molecular- weight kininogen can potentiate the risk of myocardial 
infarction	 and	 ischemic	 stroke	 (Siegerink,	 Rosendaal,	 &	 Algra,	
2012).	Our	finding	of	increased	KNG1	amount	in	HS-	RLS	patients	
provides	a	 further	support,	 together	with	 the	downregulation	of	
A1AT,	for	a	greater	risk	of	CVD,	especially	in	RLS	at	high	severity.	
This	 is	 in	 line	with	 the	 literature,	 which	 proves	 the	 presence	 of	
a	close	 relationship	between	vascular	 risk	 factors,	CVD	and	RLS	
(Schlesinger,	Erikh,	Avizohar,	Sprecher,	&	Yarnitsky,	2009;	Winter	
et	al.,	 2013).	Moreover,	 it	 is	well	 known	 that	 inflammation	 plays	
a larger role in the predisposition to CVD and that stroke may be 
mediated	 by	 inflammatory	mechanisms.	Considered	 all	 together,	
our findings strongly support and consolidate the theoretical roles 
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2017).	 Genomewide	 association	 studies	 (GWAS),	 meta-	analysis,	
twin,	 and	 family	 large-	scale	 studies	 have	 successfully	 contributed	
to	 identify	 significant	 association	between	RLS	 and	 common	vari-
ants	 in	 MEIS1,	 BTBD9,	 and	MAP2K5	 genes	 (Thireau	 et	al.,	 2017;	
Winkelmann	et	al.,	2007).	It	should	be	noted	that	our	patients	were	
not	sequenced	for	these	allelic	variations	that	however	might	be	of	
relevant interest for the study.
Moreover,	another	important	consideration	is	that	13	of	17	pa-
tients	 in	the	MMS	group,	and	15	of	17	patients	 in	HS	group,	were	
under	 treatment	with	pramipexole	 (0.25–0.75	mg/day)	before	 col-
lecting	blood	samples,	and	only	one	patient	in	the	HS	group	was	tak-
ing	also	pregabalin	(150	mg/day).	We	believe	that	medications	could	
have	 an	 effect	 on	 proteomic	 analysis;	 hence,	 further	 studies	may	
enlighten the impact of pharmacological treatment on the plasmatic 
proteome.
Finally,	 relatively	 to	 the	 rating	 scales	 used	 in	 the	 study,	 we	
found	 a	 significantly	 poorer	 sleep	 quality	 in	 HS-	RLS	 vs.	 MMS	
group,	and	a	trend	toward	a	higher	daytime	sleepiness,	along	with	




revealed a defined protein cluster related to the involvement of 
biochemical networks principally linked to inflammatory and im-
mune	response;	specifically,	the	increasing	levels	of	immunoglob-
ulins may account for the progression and severity of the disease. 
Moreover,	 the	 underexpression	 of	 A1AT	 and	 the	 upregulation	
of	 KNG1	 are	 reflective	 of	 a	 greater	 risk	 for	 HS-	RLS	 patients	 to	
develop CVD; these proteins may represent potential early diag-
nostic biomarkers for cardiovascular and autoimmune disorders. 
Altogether,	 our	 data	 could	 suggest	 additional	 insights	 into	 the	
multifactorial	 pathophysiology	 of	 the	RLS	 and	 contribute	 to	 en-
hance the inflammatory/immunological hypothesis proposed for 
the	evolution	of	RLS	process.
The proteomic analysis of plasma allowed a greater understand-
ing	 of	 RLS,	 providing	 relevant	 information	 for	 its	 diagnosis	 and	
prognosis by the identification of a promising platform of candidate 
protein	biomarkers,	which	could	also	be	considered	as	helpful	drug	
targets to develop innovative treatment strategies.








ysis,	 and	 “Fondazione	Cassa	di	Risparmio	di	Modena,	 Italy,	 for	 sup-
ported the purchase of the mass spectrometer employed in this study.
CONFLIC T OF INTERE S TS
All	authors	certify	that	they	have	no	conflict	of	interests.
ORCID
Elisa Bellei  http://orcid.org/0000-0002-6801-0446 
Serkan Ozben  http://orcid.org/0000-0002-2227-4104 
R E FE R E N C E S
Allen,	R.	P.,	Picchietti,	D.	L.,	Garcia-Borreguero,	D.,	Ondo,	W.	G.,	Walters,	
A.	 S.,	 Winkelman,	 J.	 W.,	 …	 International	 Restless	 Legs	 Syndrome	
Study	Group	 (2014).	 Restless	 legs	 syndrome/Willis-	Ekbom	disease	
diagnostic	 criteria:	 Updated	 International	 Restless	 Legs	 Syndrome	
Study	 Group	 (IRLSSG)	 consensus	 criteria	 –	 history,	 rationale,	 de-
scription,	and	significance.	Sleep Medicine,	15,	860–873.	https://doi.
org/10.1016/j.sleep.2014.03.025
Allen,	 R.	 P.,	 Picchietti,	 D.,	Hening,	W.	A.,	 Trenkwalder,	 C.,	Walters,	 A.	
S.,	&	Montplaisi,	 J.	 (2003).	Restless	 legs	 syndrome:	Diagnostic	 cri-
teria,	 special	 considerations,	 and	 epidemiology.	 A	 report	 from	 the	
restless legs syndrome diagnosis and epidemiology workshop at the 
National Institutes of Health. Sleep Medicine,	4,	101–119.	https://doi.
org/10.1016/S1389-9457(03)00010-8
American	Academy	of	Sleep	Medicine	 (2014).	The International classifi-
cation of sleep disorders – third edition (ICSD-3).	Darien,	IL:	American	
Academy	of	Sleep	Medicine.
Bai,	 S.,	 Liu,	 S.,	 Guo,	 X.,	 Qin,	 Z.,	Wang,	 B.,	 Li,	 X.,	 …	 Liu,	 Y.	 H.	 (2009).	
Proteome analysis of biomarkers in the cerebrospinal fluid of neuro-
myelitis optica patients. Molecular Vision,	15,	1638–1648.
Beck,	 A.	 T.,	 Steer,	 R.	 A.,	 &	 Carbin,	 M.	 G.	 (1988).	 Psychometric	 prop-
erties	 of	 the	 Beck	 Depression	 Inventory:	 Twenty-	five	 years	 of	




teomic analysis: Concomitant removal of non- targeted proteins. Amino 
Acids,	40,	145–156.	https://doi.org/10.1007/s00726-010-0628-x
Bellei,	E.,	Vilella,	A.,	Monari,	E.,	Bergamini,	S.,	Tomasi,	A.,	Cuoghi,	A.,	…	
Pini,	L.	A.	 (2017).	Serum	protein	changes	 in	a	 rat	model	of	chronic	
pain show a correlation between animal and humans. Scientific 
Reports,	7,	41723.	https://doi.org/10.1038/srep41723
Biswas,	 S.,	 Sharma,	 S.,	 Saroha,	A.,	 Bhakuni,	D.	 S.,	Malhotra,	 R.,	 Zahur,	
M.,	…	Asif,	 A.	 R.	 (2013).	 Identification	 of	 novel	 autoantigen	 in	 the	
synovial fluid of rheumatoid arthritis patients using an immunopro-




chiatric practice and research. Psychiatry Research,	28(2),	193–213.	
https://doi.org/10.1016/0165-1781(89)90047-4
Connor,	 J.	 R.	 (2008).	 Pathophysiology	 of	 restless	 legs	 syndrome:	
Evidence for iron involvement. Current Neurology and Neuroscience 
Reports,	8,	162–166.	https://doi.org/10.1007/s11910-008-0026-x
     |  9 of 9BELLEI Et aL.
Crutchfild,	C.	A.,	Thomas,	S.	N.,	Sokoll,	L.	J.,	&	Chan,	D.	W.	(2016).	Advances	
in mass spectrometry- based clinical biomarker discovery. Clinical 
Proteomics,	13,	1.	https://doi.org/10.1186/s12014-015-9102-9
Didriksen,	M.,	Rigas,	A.	S.,	Allen,	R.	P.,	Burchell,	B.	J.,	Di	Angelantonio,	
E.,	 Nielsen,	M.	H.,	 …	Ullum,	H.	 (2017).	 Prevalence	 of	 restless	 legs	
syndrome and associated factors in an otherwise healthy popula-
tion:	Results	from	the	Danish	Blood	Donor	Study.	Sleep Medicine,	36,	
55–61.	https://doi.org/10.1016/j.sleep.2017.04.014
Duckers,	 J.	 M.,	 Shale,	 D.	 J.,	 Stockley,	 R.	 A.,	 Gale,	 N.	 S.,	 Evans,	 B.	
A.,	 Cockcroft,	 J.	 R.,	 &	 Bolton,	 C.	 E.	 (2010).	 Cardiovascular	
and musculoskeletal co- morbidities in patients with alpha- 1- 







with alpha- 1- antitrypsin deficiency. Respiratory Research,	 18,	 171.	
https://doi.org/10.1186/s12931-017-0655-1
Fournier,	T.,	Medjoubi-N,	N.,	&	Porquet,	D.	 (2000).	Alpha-	1-	acid	glyco-




fulminant case of multiple sclerosis. International Journal of Molecular 
Sciences,	13(7676),	7693.
Gemignani,	F.,	Brindani,	F.,	&	Marbini,	A.	(2008).	Restless	legs	syndrome	
and diabetic neuropathy. Sleep,	31(3),	307.	https://doi.org/10.1093/
sleep/31.3.307
Gottenberg,	J.	E.,	Aucouturier,	F.,	Goetz,	J.,	Sordet,	C.,	Jahn,	I.,	Busson,	
M.,	 …	Mariette,	 X.	 (2007).	 Serum	 immunoglobulin	 free	 light	 chain	
assessment	in	rheumatoid	arthritis	and	primary	Sjogren’s	syndrome.	
Annals of the Rheumatic Diseases,	66(1),	23–27.
Halaby,	 D.	 M.,	 &	Mornon,	 J.	 P.	 E.	 (1998).	 The	 immunoglobulin	 super-
family:	 An	 insight	 on	 its	 tissular,	 species,	 and	 functional	 diversity.	




modulating properties. Cytokine & Growth Factor Reviews,	14,	25–34.	
https://doi.org/10.1016/S1359-6101(02)00054-0
Izci,	B.,	Ardic,	S.,	Firat,	H.,	Sahin,	A.,	Altinors,	M.,	&	Karacan,	 I.	 (2008).	
Reliability and validity studies of the Turkish version of the Epworth 
Sleepiness	Scale.	Sleep Breath,	12,	161–168.	https://doi.org/10.1007/
s11325-007-0145-7
Kaplan,	 B.,	 Golderman,	 S.,	 Yahalom,	 G.,	 Yaskariev,	 R.,	 &	 Sela,	 B.	 A.	
(2013).	Free	light	chain	monomers	in	the	diagnosis	of	multiple	scle-












heart disease among women. Circulation,	126,	 1689–1694.	 https://
doi.org/10.1161/CIRCULATIONAHA.112.112698
Nagandla,	K.,	&	De,	S.	(2013).	Restless	legs	syndrome:	Pathophysiology	
and modern management. Postgraduate Medical Journal,	 89,	 402–
410.	https://doi.org/10.1136/postgradmedj-2012-131634
Novak,	M.,	Winkelman,	J.	W.,	&	Unruh,	M.	(2015).	Restless	legs	syndrome	
in patients with chronic kidney disease. Seminars in Nephrology,	35(4),	
347–358.	https://doi.org/10.1016/j.semnephrol.2015.06.006
Patton,	 S.	M.,	 Cho,	 Y.	W.,	 Clardy,	 T.	W.,	 Allen,	 R.	 P.,	 Earley,	 C.	 J.,	 &	
Connor,	 J.	 R.	 (2013).	 Proteomic	 analysis	 of	 the	 cerebrospi-
nal fluid of patients with restless legs syndrome/Willis- Ekbom 
disease. Fluids and Barriers of the CNS,	 10,	 20.	 https://doi.
org/10.1186/2045-8118-10-20
Quaye,	I.	K.	(2008).	Haptoglobin,	inflammation	and	disease.	Transactions 
of the Royal Society of Tropical Medicine and Hygiene,	102,	735–742.	
https://doi.org/10.1016/j.trstmh.2008.04.010
Ricklin,	D.,	Hajishengallis,	G.,	Yang,	K.,	&	Lambris,	J.	D.	(2010).	Complement:	
A	 key	 system	 for	 immune	 surveillance	 and	 homeostasis.	 Nature 
Immunology,	11(9),	785–797.	https://doi.org/10.1038/ni.1923
Schlesinger,	I.,	Erikh,	I.,	Avizohar,	O.,	Sprecher,	E.,	&	Yarnitsky,	D.	(2009).	
Cardiovascular risk factors in restless legs syndrome. Movement 
Disorders,	24(11),	1587–1592.	https://doi.org/10.1002/mds.22486
Siegerink,	 B.,	 Rosendaal,	 F.	 R.,	 &	 Algra,	 A.	 (2012).	 High-	molecular-	
weight kininogen and the risk of myocardial infarction and isch-
emic	 stroke	 in	 young	 women:	 The	 RATIO	 case-	control	 study.	




nomic	 imbalance	 in	 Restless	 Legs	 Syndrome.	 Scientific Reports,	 7,	
46620.	https://doi.org/10.1038/srep46620
Torkildsen,	O.,	Stansberg,	C.,	Angelskar,	S.	M.,	Kooi,	E.	 J.,	Geurts,	 J.	 J.,	
van	der	Valk,	P.,	…	Bø,	L.	 (2010).	Upregulation	of	 immunoglobulin-	
related genes in cortical sections from multiple sclerosis patients. 
Brain Pathology,	20,	720–729.
Trotti,	L.	M.	 (2017).	Restless	 legs	syndrome	and	sleep-	related	movement	
disorders. Continuum : Lifelong Learning in Neurology,	23(4),	1005–1016.
Weinstock,	 L.	 B.,	 Walters,	 A.	 S.,	 &	 Paueksakon,	 P.	 (2012).	 Restless	
legs	 syndrome	 –	 Theoretical	 roles	 of	 inflammatory	 and	 immune	









Winter,	 A.	 C.,	 Berger,	 K.,	 Glynn,	 R.	 J.,	 Buring,	 J.	 E.,	 Gaziano,	 J.	 M.,	
Schürks,	 M.,	 &	 Kurth,	 T.	 (2013).	 Vascular	 risk	 factors,	 cardio-
vascular	 disease,	 and	 restless	 legs	 syndrome	 in	 men.	 American 
Journal of Medicine,	 126,	 228–235.	 https://doi.org/10.1016/j.
amjmed.2012.06.039
Xie,	 Z.,	 Dai,	 J.,	 &	Wu,	 Y.	 (2016).	High-	molecular-	weight	 kininogen	 and	
its cleavage product bradykinin are critical in the pathogenesis of 
autoantibody- induced arthritis. Journal of Immunology,	196(124),	112.
How to cite this article:	Bellei	E,	Monari	E,	Ozben	S,	et	al.	
Discovery of restless legs syndrome plasmatic biomarkers by 
proteomic analysis. Brain Behav. 2018;e01062. https://doi.
org/10.1002/brb3.1062
